The 2021 China International Service Trade Fair will be held in Beijing from September 2 to 7
Professor Yong Huo of Peking University First Hospital said: “In the field of cardiovascular disease prevention and treatment, we have been exploring a cardiovascular disease prevention and treatment system suitable for Chinese characteristics for many years
Experts at the meeting believed that although the current statin therapy is effective in reducing LDL-C, the Chinese population using high-dose statins is more likely to have the risk of drug-induced myopathy and increased liver enzymes than other ethnic groups, so most Chinese people can only receive medium-dose statin treatment, and poor treatment compliance has further led to a low rate of compliance with statin treatment in patients
The small interfering nucleic acid (siRNA) therapy has received extensive attention from experts in the forum.
Professor Yuan Zuyi from the First Affiliated Hospital of Xi’an Jiaotong University believes , “The application of siRNA therapy in the cardiovascular field will lead the treatment and management of common chronic diseases into a new therapeutic revolution
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
